Newsfile Corp
01 Jun 2026, 18:49 UTC · 3h ago
Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares
Search tags
Newsfile Corp
01 Jun 2026, 18:49 UTC · 3h ago
Search tags
Story key points
3 claims · impact-rated
Thiogenesis Therapeutics increased its private placement size from 16 million to 18 million common shares due to strong investor demand. — Upsizing a funding round due to demand indicates strong institutional or private interest in the company's pipeline.
+0.40Net proceeds will fund clinical development of TTI-0102, including a Phase 2a study in Leigh syndrome spectrum and an investigator-initiated study in cystinosis. — Directly ties the capital raise to tangible clinical milestones and pipeline expansion.
+0.30The company will raise approximately $9 million in gross proceeds from the offering at a price of $0.50 per share. — Increases the company's cash runway, which is critical for clinical-stage biotech firms.
+0.20Ticker attribution
Model heads
Continue reading
6 related stories
The company increased the size of its private placement due to strong investor demand, providing more capital for clinical development.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
2 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
Globe News Wire
12h ago
